PHARMARON BEIJING CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.9 CNY | +4.71% |
|
+5.82% | -27.88% |
| Apr. 30 | Pharmaron Beijing's Profit Rises 17% in 2023 | MT |
| Apr. 29 | Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 12.73B 1.76B | Sales 2025 * | 14.8B 2.05B | Capitalization | 33.92B 4.7B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.6B 221M | Net income 2025 * | 2.16B 299M | EV / Sales 2024 * | 2.94 x |
| Net Debt 2024 * | 3.49B 484M | Net Debt 2025 * | 2.73B 378M | EV / Sales 2025 * | 2.48 x |
| P/E ratio 2024 * |
22.5
x | P/E ratio 2025 * |
17.5
x | Employees | - |
| Yield 2024 * |
1.12% | Yield 2025 * |
1.38% | Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.71% | ||
| 1 week | +5.82% | ||
| Current month | +5.82% | ||
| 1 month | +2.60% | ||
| 3 months | -0.81% | ||
| 6 months | -39.70% | ||
| Current year | -27.88% |
1 week
19.82
21.31
1 month
17.8821.31
Current year
17.8828.90
1 year
17.8837.00
3 years
17.88108.71
5 years
14.22108.71
10 years
4.08108.71
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
FOU | Founder | 55 | 04-06-30 |
Bei Zheng
FOU | Founder | 57 | 04-06-30 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwan Hung Tsang
BRD | Director/Board Member | 60 | 19-08-14 |
Jia Qing Li
BRD | Director/Board Member | 51 | 16-10-26 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.17% | 0 M€ | -12.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 20.9 | +4.71% | 39,713,090 |
| 24-05-08 | 19.96 | -1.82% | 21,141,600 |
| 24-05-07 | 20.33 | -0.44% | 18,718,920 |
| 24-05-06 | 20.42 | +3.39% | 29,187,720 |
End-of-day quote Shenzhen S.E., May 08, 2024
More quotes
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
20.9
CNY
Average target price
24.15
CNY
Spread / Average Target
+15.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.88% | 4.7B | |
| +23.37% | 47.02B | |
| +49.79% | 41.86B | |
| -0.94% | 41.76B | |
| -4.32% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- 300759 Stock